Dihydroartemisinin for COVID-19

Dihydroartemisinin may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed dihydroartemisinin in detail.

Protocol efficacy and cost by country

Treatment protocols varied widely

November 2026
Efficacy of protocol
SeychellesSCIcelandISBelizeBZMaltaMTLuxembourgLUMontenegroMEBhutanBTGuyanaGYComorosKMFijiFJDjiboutiDJCyprusCYMauritiusMUEstoniaEETrinidad and TobagoTTEquatorial GuineaGQBahrainBHLatviaLVGuinea-BissauGWSloveniaSINorth MacedoniaMKLesothoLSGabonGABotswanaBWGambiaGMNamibiaNALithuaniaLTAlbaniaALQatarQAJamaicaJMArmeniaAMMongoliaMNBosnia and HerzegovinaBAUruguayUYEritreaERGeorgiaGECroatiaHRPanamaPAMauritaniaMRNew ZealandNZCentral African RepublicCFIrelandIELiberiaLRCosta RicaCRNorwayNOSlovakiaSKCongoCGFinlandFIDenmarkDKSingaporeSGEl SalvadorSVKyrgyzstanKGNicaraguaNILebanonLBLibyaLYBulgariaBGParaguayPYHong KongHKSierra LeoneSLTogoTGSwitzerlandCHIsraelILSerbiaRSPapua New GuineaPGAustriaATBelarusBYTajikistanTJHungaryHUUnited Arab EmiratesAEHondurasHNSwedenSEAzerbaijanAZPortugalPTJordanJOGreeceGRCzechiaCZDominican RepublicDOSouth SudanSSCubaCUHaitiHTBelgiumBEBoliviaBOTunisiaTNBurundiBIBeninBJRwandaRWGuineaGNZimbabweZWChadTDCambodiaKHSenegalSNNetherlandsNLSyriaSYEcuadorECGuatemalaGTZambiaZMKazakhstanKZMalawiMWRomaniaROMaliMLBurkina FasoBFSri LankaLKTaiwanTWNigerNEAustraliaAUCĂ´te d'IvoireCICameroonCMMadagascarMGVenezuelaVENepalNPYemenYEGhanaGHMozambiqueMZMalaysiaMYAngolaAOPeruPEUzbekistanUZSaudi ArabiaSAMoroccoMACanadaCAPolandPLAfghanistanAFIraqIQUkraineUASudanSDAlgeriaDZArgentinaARUgandaUGSpainESColombiaCOSouth KoreaKRKenyaKEMyanmarMMSouth AfricaZAItalyITFranceFRUKGBThailandTHGermanyDEIranIRTurkeyTRDR CongoCDVietnamVNEgyptEGPhilippinesPHEthiopiaETJapanJPMexicoMXRussiaRUBangladeshBDNigeriaNGBrazilBRPakistanPKIndonesiaIDUSAUSIndiaINChinaCNmore effective, cheaperless effective, costlier
0%20%40%60%
$0$500$1,000$1,500
Cost per course

Cost and estimated efficacy of national COVID-19 protocols; area is proportional to population. Countries are named where there is room, with more populous countries first and in darker type; hover any dot for details.

Amahong et al., An integrative meta-analysis of SARS-CoV-2 RNA–protein interactomes identifies conserved host factors shared with other RNA viruses, Briefings in Functional Genomics, doi:10.1093/bfgp/elag001
Abstract RNA viruses cause substantial global disease burden and depend on host RNA-binding proteins and translation machinery. However, it remains unclear which host factors are robustly engaged across independent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA interactome studies and to what extent these factors are shared with other RNA viruses. Here, we perform an integrative meta-analysis of eight published SARS-CoV-2 RNA–protein interactomes and compare them with corresponding Influenza A virus, Zika virus, and Dengue virus datasets to define conserved host networks and prioritize candidate host-directed antiviral targets. By integrating multiple datasets and applying ClusterProfiler together with curated pathway resources (KEGG, Reactome, WikiPathways, and Gene Ontology), we systematically characterize the functional landscape of SARS-CoV-2 RNA–protein interactions. The consensus SARS-CoV-2 interactome is enriched for mRNA processing, translation, RNA surveillance and innate immune functions. Cross-viral comparison identifies 275 host proteins shared across all four RNA viruses, forming interconnected modules that include key translation factors (EEF1A1, EIF4A1, EIF3H) and RNA-binding proteins (Nucleolin, ILF3). Drug–target annotation prioritizes 21 proteins with 35 approved or investigational modulators for host-directed antiviral repurposing. Together, these findings generate a consensus map of conserved host dependencies and highlight prioritized targets for future mechanistic and translational studies. Research Highlights Integrated SARS-CoV-2 datasets and compared with, Influenza A virus, Zika virus, Dengue virus. Identified 275 host proteins shared across these four pathogens. Conserved proteins were enriched in translation, RNA processing, and innate immune pathways. Prioritized 21 host targets and 35 drugs for antiviral repurposing.
Amtaghri et al., Phytomedical compounds as promising therapeutic agents for COVID-19 targeting angiotensin-converting enzyme 2: a review, Journal of Pharmacy and Pharmacology, doi:10.1093/jpp/rgae101
Abstract Aims The aim of the present review was to highlight natural product investigations in silico and in vitro to find plants and chemicals that inhibit or stimulate angiotensin-converting enzyme 2 (ACE-2). Background The global reduction of incidents and fatalities attributable to infections with SARS-CoV-2 is one of the most public health problems. In the absence of specific therapy for coronavirus disease 2019 (COVID-19), phytocompounds generated from plant extracts may be a promising strategy worth further investigation, motivating researchers to evaluate the safety and anti-SARS-CoV-2 effectiveness of these ingredients. Objective To review phytochemicals in silico for anti-SARS-CoV-2 activity and to assess their safety and effectiveness in vitro and in vivo. Methods The present review was conducted using various scientific databases and studies on anti-SARS-CoV-2 phytochemicals were analyzed and summarized. The results obtained from the in silico screening were subjected to extraction, isolation, and purification. The in vitro studies on anti-SarcoV-2 were also included in this review. In addition, the results of this research were interpreted, analyzed, and documented on the basis of the bibliographic information obtained. Results This review discusses recent research on using natural remedies to cure or prevent COVID-19 infection. The literature analysis shows that the various herbal preparations (extracts) and purified compounds can block the replication or entrance of the virus directly to carry out their anti-SARS-CoV-2 effects. It is interesting to note that certain items can prevent SARS-CoV-2 from infecting human cells by blocking the ACE-2 receptor or the serine protease TMPRRS2. Moreover, natural substances have been demonstrated to block proteins involved in the SARS-CoV-2 life cycle, such as papain- or chymotrypsin-like proteases. Conclusion The natural products may have the potential for use singly or in combination as alternative drugs to treat/prevent COVID-19 infection, including blocking or stimulating ACE-2. In addition, their structures may provide indications for the development of anti-SARS-CoV-2 drugs.
Girgis et al., Indole-based compounds as potential drug candidates for SARS-CoV-2, MDPI AG, doi:10.20944/preprints202308.0746.v1
The COVID-19 pandemic has posed a significant threat to society in recent times, endangering human health, life, and economic well-being. The disease spreads quickly due to the highly infectious SARS-CoV-2 virus, which has undergone numerous mutations. Despite intense research efforts by the scientific community since its emergence in 2019, no effective therapeutics have been discovered yet. While some repurposed drugs have been used to control the global outbreak and save lives, none have proven universally effective, particularly for severely infected patients. Although the spread of the disease is generally under control, anti-SARS-CoV-2 agents are still needed to combat current and future infections. This study reviews some of the most promising repurposed drugs containing indolyl heterocycle, which is an essential scaffold of many alkaloids with diverse bio-properties in various biological fields. The study also discusses natural and synthetic indole-containing compounds with anti-SARS-CoV-2 properties, as well as computer-aided drug design (in-silico studies) for optimizing anti-SARS-CoV-2 hits/leads.
Navacchia et al., Insights into SARS-CoV-2: Small-Molecule Hybrids for COVID-19 Treatment, Molecules, doi:10.3390/molecules29225403
The advantages of a treatment modality that combines two or more therapeutic agents with different mechanisms of action encourage the study of hybrid functional compounds for pharmacological applications. Molecular hybridization, resulting from a covalent combination of two or more pharmacophore units, has emerged as a promising approach to overcome several issues and has also been explored for the design of new drugs for COVID-19 treatment. In this review, we presented an overview of small-molecule hybrids from both natural products and synthetic sources reported in the literature to date with potential antiviral anti-SARS-CoV-2 activity.
Niarakis et al., Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859
IntroductionThe COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. MethodsExtensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors.ResultsResults revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. DiscussionThe key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.
Ramezani et al., Effect of herbal compounds on inhibition of coronavirus; A systematic review and meta-analysis, Authorea, Inc., doi:10.22541/au.170668000.04030360/v1
The outbreak of the new coronavirus (COVID-19) has been transferred exponentially. There are many articles that have found the inhibitory effect of plant extracts or plant compounds on the coronavirus family. In this study, we want to use systematic review and meta-analysis to answer the question of which herbal compound can be more effective against the coronavirus. The present study is based on the guidelines for conducting meta-analyzes. An extensive search was conducted in the electronic database, and based on the inclusion and exclusion criteria, articles were selected and data screening was performed. Quality control of articles was performed. Data analysis was carried out in STATA software. The results showed that alkaloid compounds had a good effect in controlling the coronavirus and reducing viral titer. Trypthantrin, Sambucus extract, S. cusia extract, Boceprevir and Indigole B, dioica agglutinin urtica had a good effect on reducing the virus titer but their selectivity index has not been reported and it is recommended to determine for these compounds. Also among the compounds that had the greatest effect on virus inhibition, including Saikosaponins B2, SaikosaponinsD, SaikosaponinsA and Phillyrin, had an acceptable selectivity index greater than 10. Andrographolide showed the highest selectivity index on SARS-COV2, while virus titration and virus inhibition were not reported. The small number of studies that used alkaloid compounds was one of the limitations and it is suggested to investigate the effect of more alkaloid compounds against the coronavirus for verifying its effect.
Shaer et al., Potential of Artemisia annua Bioactives as Antiviral Agents Against SARS-CoV-2 and Other Health Complications, Pharmaceuticals, doi:10.3390/ph18121904
This review highlights Artemisia annua, a medicinal plant which grows in the Kingdom of Saudi Arabia, known for its abundant therapeutic properties. A. annua serves as a rich source of various bioactive compounds, including sesquiterpenoid lactones, flavonoids, phenolic acids, and coumarins. Among these, artemisinin and its derivatives are most extensively studied due to their potent antimalarial properties. Extracts and isolates of A. annua have demonstrated a range of therapeutic effects, such as antioxidant, anticancer, anti-inflammatory, antimicrobial, antimalarial, and antiviral properties. Given its significant antiviral activity, A. annua could be investigated for the development of new nutraceutical bioactive compounds to combat SARS-CoV-2. Artificial Intelligence (AI) can assist in drug discovery by optimizing the selection of more effective and safer natural bioactives, including artemisinin. It can also predict potential clinical outcomes through in silico modeling of protein–ligand interactions. In silico studies have reported that artemisinin and its derivatives possess a strong ability to bind with the Lys353 and Lys31 hotspots of the SARS-CoV-2 spike protein, demonstrating their effective antiviral effects against COVID-19. This integrated approach may accelerate the identification of effective and safer natural antiviral agents against COVID-19.